Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07553637 · ClinicalTrials.gov registry record · Phase 2
ALTO-207 in Adults With Treatment-resistant Depression (TRD)
A Phase 2 study, sponsored by Alto Neuroscience.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 178
- Enrollment target
NCT07553637: Recruiting Phase 2 study, sponsored by Alto Neuroscience.
NCT07553637 is a Phase 2 study that is actively recruiting participants, run by Alto Neuroscience. The registered enrollment target is 178 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (34% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07553637, a Phase 2 study, is actively recruiting participants, sponsored by Alto Neuroscience.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 178 participants
- Enrollment target
Study Summary
The purpose of this trial is to measure depressive symptoms following treatment with ALTO-207 compared with placebo in participants with TRD.
Primary Outcome
Montgomery Asberg Depression Rating Scale (MADRS) is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is scored from 0 (item not present or normal) to 6 (severe or continuous presence
Interventions
- DRUG Placebo
- DRUG ALTO-207
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 178 participants |
| Start Date | 2026-05 |
| Est. Completion | 2027-12 |
| Phase | Phase 2 |
What NCT07553637 shows while recruiting
NCT07553637 is an interventional study that assigns participants to a tested intervention. The registered 178 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (34% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07553637 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07553637 about?
NCT07553637 is a clinical study titled "ALTO-207 in Adults With Treatment-resistant Depression (TRD)". The purpose of this trial is to measure depressive symptoms following treatment with ALTO-207 compared with placebo in participants with TRD.
What is the current status of trial NCT07553637?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 178 participants. The study started on 2026-05. Estimated completion is 2027-12.
What interventions are being tested in trial NCT07553637?
The interventions under investigation include: Placebo (DRUG), ALTO-207 (DRUG).
Who is sponsoring clinical trial NCT07553637?
This trial is sponsored by Alto Neuroscience, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07553637's enrollment target sits among peer trials
178 391st of 2000 higher than 1,607 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03642002 · 178 participants · NA
The Effects of Music Therapy on Adult Patients Requiring Mechanical Ventilation in the ICU
- NCT04227847 · 178 participants · Phase 1
A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies
- NCT04855214 · 178 participants
Evaluating the Experience of Upper Limb Prosthesis Use
- NCT05391126 · 178 participants · NA
GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia